

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Christophe BONNY**

Confirmation No.: **5087**

Application No.: **10/500,804**

Group Art Unit: **1649**

Filed: **January 7, 2005**

Examiner: **Stephen Gucker**

For: **CELL-PERMEABLE PEPTIDE
INHIBITORS OF THE JNK SIGNAL
TRANSDUCTION PATHWAY**

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(d)

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant brings to the attention of the Examiner the documents listed on the attached PTO-1449 form. This Information Disclosure Statement is being filed in conjunction with a Request for Examination (RCE). Accordingly, under 37 C.F.R. §1.97(b), no fee is due. Nonetheless, in the event that any fees are due to maintain the pendency of this application, the undersigned authorizes the Commissioner to charge any fees due to Deposit Account 50-0310.

With the exception of U.S. Patents, copies of the listed documents are attached. Applicant respectfully requests that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made and does not constitute an admission that each or all of the listed documents are either material or that they constitute "prior art." Applicant reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Dated: **July 21, 2009**
Morgan, Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP

 /Todd Buck/
Todd B. Buck
Registration No. 48,574